Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Eli Lilly and Co LLY

Healthcare Drug Manufacturers - Major
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes... see more

Current News (NYSE:LLY)

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor

PR Newswire 2 days ago

Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium

PR Newswire 11 days ago

Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting

PR Newswire 11 days ago

Lilly announces plans to open Lilly Gateway Labs site in Philadelphia

PR Newswire November 19, 2025

Lilly to participate in Citi's 2025 Global Healthcare Conference

PR Newswire November 18, 2025

Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'

PR Newswire November 10, 2025

Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

PR Newswire November 6, 2025

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans

PR Newswire November 6, 2025

Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight

PR Newswire November 6, 2025
View More News ››

Opinion & Analysis (NYSE:LLY)

Morning Market Outlook for June 11, 2024

TheUpTrend June 11, 2024

Eli Lilly Trades Up 15% on Positive Phase 3 Breast Cancer Trial Results

Streetwise Reports June 17, 2020

Possible 'best-in-class' alzheimer's drug candidate offers 'disruptive' potential

The Life Sciences Report September 21, 2017

The ProMIS of an Alzheimer's cure

The Life Sciences Report May 4, 2017

Diffusion Pharmaceuticals takes aim at brain cancer: CEO David Kalergis

The Life Sciences Report April 1, 2016

The next leg of the health care boom is under way

Dr. David Eifrig June 15, 2015
View More Opinion ››

Bullboard Posts (NYSE:LLY)

Don’t Miss the Next Eli Lilly Payout Date

For investors tracking Eli lilly dividend date, the next key date to note is August15,2025—that’s the exdividend and record date for the...
EvansWilson - August 21, 2025

LLY

Is setting up to run again.
jboom70 - February 21, 2025

Monster

Eli Lilly and Company is a monster. $844.16 72.015 |  9.33% Bid:  843.34 x 400 Ask...
E30S14 - August 8, 2024

RE:RE:Another new high for LLY

This little soldier keeps on thumpin' and pumpin' $904.61 14.5 |  1.63% Bid:  ...
E30S14 - June 25, 2024

RE:Another new high for LLY

Yet another new high for LLY. $883.33 16.03 |  1.85% Bid:  878.36 x 200 Ask: ...
E30S14 - June 13, 2024

Another new high for LLY

I love this company and the stock. But how much higher can LLY go?? $865.00 15.01 |  1.77% Bid:&...
E30S14 - June 10, 2024
View more Bullboard ››

Nuclear Vision Ltd.

Nuclear Vision Ltd.

Nuclear Vision Limited operates as a uranium exploration company. Its material property is the Regnault Project that consists ...
View More »